Diagnostic Code 7724 · 38 CFR §4.117
Solitary plasmacytoma is a single tumor made up of abnormal plasma cells (the same type of cells involved in multiple myeloma, but limited to one location instead of widespread throughout the bone marrow). It can occur in bone (solitary bone plasmacytoma, most commonly in the spine or pelvis) or in soft tissue outside the bone (extramedullary plasmacytoma, often in the upper respiratory tract). Symptoms depend on the location — bone plasmacytoma may cause localized pain, fractures at the tumor site, or spinal cord compression, while soft tissue plasmacytoma may cause obstruction or bleeding at the affected site. The key concern with solitary plasmacytoma is that a significant percentage of cases eventually progress to multiple myeloma over the years. For veterans, plasmacytoma may be linked to radiation exposure, chemical exposures, or Agent Orange. The VA assigns a mandatory 100 percent rating during active disease and treatment, then reassesses based on residual effects and monitoring needs.
| Rating | Criteria |
|---|---|
| 100% | Active solitary plasmacytoma or during treatment (radiation therapy, surgery, or chemotherapy). The 100 percent rating continues for six months after treatment ends, at which point the VA reassesses based on residual effects. After treatment, residuals such as bone damage, pain at the tumor site, or ongoing monitoring for progression to multiple myeloma are rated under applicable diagnostic codes. |
Tissue biopsy confirming plasmacytoma with plasma cell pathology is the essential diagnostic evidence. Imaging (MRI, PET/CT) showing the solitary lesion and confirming that disease has not spread to other sites distinguishes this from multiple myeloma. Bone marrow biopsy showing less than 10 percent plasma cells (ruling out multiple myeloma) is typically required. Blood and urine protein electrophoresis help characterize the condition. Treatment records documenting radiation, surgery, or other interventions are needed. For service connection, documentation of qualifying toxic exposure and a hematology or oncology nexus opinion are important.
Yes. Studies show that a meaningful percentage of solitary bone plasmacytomas eventually progress to multiple myeloma, sometimes years or even decades later. This is why long-term monitoring with blood work and imaging is essential even after successful treatment. If progression occurs, you should file for an updated rating.
Solitary plasmacytoma is a single tumor of abnormal plasma cells in one location, while multiple myeloma involves widespread plasma cell cancer throughout the bone marrow. The distinction is made through bone marrow biopsy and full-body imaging. Plasmacytoma is rated under DC 7724 and multiple myeloma under other applicable codes.